22 March 2025 in Biomedicine & Pharmacotherapy
Delavirdine is an anti-HIV agent with structural similarity (presence of methanesulfonamide group) to well-known rapid delayed rectifier potassium current (IKr) inhibitors like dofetilide and E-4031. In spite of this and the fact, that IKr blockade can lead to long QT syndrome with a risk of early afterdepolarization, cardiac arrhythmia and even sudden cardiac death development, there is no information on the cardiac electrophysiological effects of the delavirdine. Therefore, we examined the concentration-dependent acute effects of delavirdine on action potential morphology and on the underlying ion currents in enzymatically dispersed canine ventricular cardiomyocytes, as well as in a hERG-channel- and NaV1.5-expressing cell lines. Delavirdine application in the µM concentration range resulted in rapid, potent and reversible blockade of expressed hERG channels. NaV1.5 channels were slightly reduced by delavirdine. Moreover, APD increase, reduction of maximal rates of phases 1 and 3 and a small increase of Plateau20 amplitude were detected in canine left ventricular isolated cardiomyocytes in a concentration-dependent manner. Accordingly, the delavirdine-sensitive current contained an early and transient, as well as a late outward component corresponding to phases 1 and 3 of the AP. These results support the delavirdine-evoked inhibition of IKr, transient outward potassium current as well as sodium current. As these concentrations are similar to therapeutic plasma values (7-30 µM), delavirdine application might carry some risk of cardiac side effects especially in HIV-infected patients with altered cardiac function or patients with co-administration of drugs metabolized by certain cytochrome P450 isoforms.
20 May 2026 in Biomedicine & Pharmacotherapy
The development of new drug molecules targeting voltage-gated ion channels has declined in the last decade, highlighting the need for novel lead compounds with new mechanisms of action. We previously identified NZ-58 as a small-molecule inhibitor of the HV1 proton channel. At 50 μM NZ-58 also potently blocked voltage-gated Na+ and K+ channels, but not the non-voltage-gated ones, suggesting an interaction with the voltage-sensor domains (VSDs). At lower concentrations (0.5-10 μM), it altered gating kinetics with minimal amplitude changes. NZ-58 significantly slowed the current activation kinetics of the channels, as well as the VSD-linked fast inactivation of the NaV1.5 channel, thereby substantially increasing total charge transfer. The loss-of-function Brugada mutant NaV1.5-R1632C was similarly enhanced by NZ-58, but the effect was not present on slowly inactivating KV channels. Gating current measurements confirmed a direct effect on VSD movement. The voltage-dependence of activation and steady-state inactivation were not altered in NaV1.5, but its recovery from inactivation was slowed. NZ-58 was able to bind to the channels in the closed state, not requiring the activated conformation of the VSDs, and it could exert its effects when applied from either side of the membrane. Being non-selective, NZ-58 is not an ideal lead compound for therapeutic ion channel modulation. However, considering that many clinically used ion channel modulators are multi-target "dirty drugs" that still achieve therapeutic benefit, and the unique features of its interactions with voltage-gated channels, we suggest that NZ-58 is worthy of further investigations as a prospective ion channel modulator lead compound.